share_log

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

Nona Biosciences與kodiak sciences合作開發針對眼科疾病的下一代抗體療法
PR Newswire ·  12/10 10:18

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences Inc. (Nasdaq: KOD). This partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona's proprietary Harbour Mice fully human antibody platform.

劍橋,馬薩諸塞州,2024年12月9日 /PRNewswire/ -- Nona Biosciences是一家全球生物技術公司,提供從「理念到IND」(I到ITM)的整體解決方案,涵蓋目標驗證和抗體發現到臨床前研究。今天宣佈與Kodiak Sciences Inc.(納斯達克:KOD)達成合作。此次合作旨在推進新型多靶點抗體的發現,以治療眼科疾病,利用Nona獨有的Harbour Mice完全人源抗體平台。

The Harbour Mice platform generates fully human monoclonal antibodies in both the two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. The HCAb Harbour Mice platform, in particular, is transforming antibody development by producing unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. Under the agreement, Kodiak Sciences gains the right to use both the H2L2 and HCAb Harbour Mice platforms in multiple programs for therapeutic antibody discovery and development.

Harbour Mice平台以H2L2格式和僅重鏈(HCAb)格式生成完全人源的單克隆抗體,消除了額外工程或人源化的需求。特別是HCAb Harbour Mice平台正在通過生產獨特的、完全人源的重鏈抗體,這些抗體的大小約爲傳統IgG的一半,從而改變抗體開發,爲下一代抗體療法提供了顯著優勢。在協議下,Kodiak Sciences獲得了在多項程序中使用H2L2和HCAb Harbour Mice平台進行治療性抗體發現和開發的權利。

"We are pleased to collaborate with Kodiak Sciences to advance novel antibody therapies for ophthalmic diseases," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. "This agreement further validates our proprietary Harbour Mice technology platform. With Nona's industry-leading technology and expertise, we look forward to supporting Kodiak Sciences in accelerating their next-generation therapeutic antibody development and bringing more innovative therapies to patients."

Nona Biosciences主席萬景松博士表示:「我們很高興與Kodiak Sciences合作,推進新型抗體療法以治療眼科疾病。這項協議進一步驗證了我們獨特的Harbour Mice技術平台。憑藉Nona在行業內領先的技術和專業知識,我們期待着支持Kodiak Sciences加速他們的下一代治療抗體開發,併爲患者帶來更多創新療法。」

"Retinal diseases involve a complex etiology, so advancing more effective therapies will require targeting multiple pathways at once," said Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences Inc. "We are thrilled to announce our partnership with Nona Biosciences, leveraging their advanced Harbour Mice platforms and robust expertise in antibody discovery. This collaboration will accelerate our mission to create next generation biotherapeutics, combining our strengths to bring innovative treatments to patients in need."

Kodiak Sciences Inc.主席兼首席執行官萬維克托·佩爾羅斯表示:「視網膜疾病的病因複雜,因此推進更有效的療法將需要同時針對多個途徑。我們很高興地宣佈與Nona Biosciences的合作,利用他們先進的Harbour Mice平台和強大的抗體發現專業知識。這一合作將加速我們創造下一代生物治療藥物的使命,結合我們的優勢爲有需要的患者提供創新治療。」

About Nona Biosciences

關於Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice platforms and the experienced therapeutic antibody discovery team.

Nona Biosciences是一家全球生物技術公司,致力於前沿科技創新,提供從「創意到IND」(「I到ITM」)的整體解決方案,涵蓋從靶點驗證、抗體發現到臨床前研究的各個環節。其整合的抗體及抗體相關發現服務,採用多種方式,包括抗原製備、動物免疫、單個b細胞篩選到抗體先導生成和工程化、開發性評估及藥理評價,利用Harbour Mice平台的優勢和經驗豐富的治療性抗體發現團隊。

Harbour Mice generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: .

Harbour Mice以經典的兩輕鏈和兩重鏈(H2L2)格式以及僅重鏈(HCAb)格式產生完全人源性單克隆抗體。結合Harbour Mice和單個b細胞克隆平台,Nona Biosciences專注於推動全球變革性下一代藥物的發明。如需更多信息,請訪問:。

About Kodiak Sciences Inc.

關於Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. For more information, please visit .

Kodiak Sciences(納斯達克:KOD)是一家生物製藥公司,致力於研究、開發和商業化變革性治療藥物,以治療廣泛的視網膜疾病。我們專注於將新科學應用於下一代視網膜藥物的設計和製造,旨在預防和治療全球失明的主要原因。如需更多信息,請訪問。

SOURCE Nona Biosciences

來源:Nona Biosciences

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
意見領袖
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
已選擇加入
GET STARTED
開始
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論